Tag:
Gleevec
Latest Headlines
Latest Headlines
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
U.S. questions India's IP regime after Nexavar move
Is intellectual property safe in India? That's the question drugmakers--and now U.S. officials--are asking.
Novartis cancer drugs stymie deadly Ebola virus
A pair of Novartis ( $NVS ) leukemia drugs effectively attacked the highly lethal Ebola virus in lab tests, providing clues about what it might take to finally march forward with a treatment against the killer bug.
AB soars on promising survival data from Phase II tumor study
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment,
Kedem adapting Novartis' Gleevec to dissolve under tongue
Kedem Pharmaceuticals has begun developing a child-friendly version of Novartis' ( $NVS ) cancer blockbuster Gleevec that would have a decent taste and dissolve under the tongue. In announcing...
Will Gleevec, Sprycel researchers get a call from Stockholm?
Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ( $NVS ) and
Novartis, Roche blockbusters shine at ASCO
While experimental therapies grab a major chunk of the attention at the annual ASCO meeting, existing drugs have their share of new data to crow about. Here's a roundup of the biggest news coming out
Re-engineered Gleevec eliminates a side effect
Scientists have re-engineered the blockbuster oncology drug Gleevec to eliminate a serious cardiovascular risk, taking a new approach that could offer a significant improvement for "hundreds" of
Novartis wins FDA approval for Tasigna
Novartis has won FDA approval of Tasigna for patients with chronic myeloid leukemia who are resistant to Gleevec . Patients
China surges past India in drug discovery work
China's willingness to get aggressive in protecting biopharma's intellectual property is being credited with its surge past India in the total number of completed and ongoing clinical trials. An
